Valuation: Polaris Group

Market Cap 10.49B 324M 283M 261M 241M 454M 31.18B 464M 3.12B 1.23B 15.27B 1.22B 1.19B 52.56B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 11.01B 340M 297M 274M 252M 476M 32.71B 486M 3.27B 1.29B 16.02B 1.28B 1.25B 55.15B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
37.54%
Yield 2024 *
-
Yield 2025 -
1 day-4.69%
1 week-6.15%
Current month-9.96%
1 month-7.58%
3 months-35.11%
6 months-62.69%
Current year-60.77%
1 week 12.05
Extreme 12.05
13
1 month 12.05
Extreme 12.05
14.35
Current year 12.05
Extreme 12.05
35.95
1 year 12.05
Extreme 12.05
44.55
3 years 12.05
Extreme 12.05
91.1
5 years 12.05
Extreme 12.05
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-4.69%-6.15%-67.72%-85.91% 341M
+3.90%-0.39%+376.72%+599.59% 38.09B
-1.70%+4.46%+7.46%+57.67% 35.29B
-2.01%-0.76%+26.35%-6.83% 35.13B
+0.06%+0.34%+2.32%+29.30% 27.22B
+0.46%-3.49% - - 16.14B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 13.89B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average -0.30%-0.83%+190.77%+149.99% 20.63B
Weighted average by Cap. +0.19%-0.72%+168.42%+182.65%

Financials

2024 2025
Net sales 107M 3.3M 2.89M 2.66M 2.45M 4.63M 318M 4.73M 31.83M 12.52M 156M 12.4M 12.13M 536M 40.6M 1.25M 1.09M 1.01M 931K 1.76M 121M 1.79M 12.08M 4.75M 59.09M 4.71M 4.6M 203M
Net income -2.5B -77.23M -67.49M -62.28M -57.4M -108M -7.44B -111M -744M -293M -3.64B -290M -284M -12.54B -3.93B -121M -106M -97.72M -90.08M -170M -11.67B -174M -1.17B -459M -5.72B -455M -445M -19.68B
Net Debt 9.19M 284K 248K 229K 211K 397K 27.32M 406K 2.73M 1.08M 13.38M 1.07M 1.04M 46.05M 517M 15.95M 13.94M 12.86M 11.86M 22.35M 1.54B 22.84M 154M 60.47M 752M 59.9M 58.59M 2.59B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
17/07/26 NT$12.20 -4.69% 1,333,703
16/07/26 NT$12.80 +2.40% 673,380
15/07/26 NT$12.50 +2.04% 804,770
14/07/26 NT$12.25 -2.39% 1,431,018
13/07/26 NT$12.55 -3.46% 1,830,748
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock